Dopamine D1 receptor (DRD1) genetic polymorphism: Pleiotropic effects on heritable renal traits

Kidney International

Volumn 76, Issue 10, 2009, Pages 1070-1080

  Fung, Maple M ^a   Rana, Brinda K ^b   Tang, Chih Min ^b   Shiina, Tetsuo ^b   Nievergelt, Caroline M ^b   Rao, Fangwen ^a   Salem, Rany M ^a,c   Waalen, Jill ^c   Ziegler, Michael G ^a   Insel, Paul A ^a,b   O'Connor, Daniel T ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Dopamine; DRD1; Genetic polymorphism; GFR; Kidney

Indexed keywords

CREATININE; DOPAMINE 1 RECEPTOR; MESSENGER RNA; URIC ACID;

5' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; CAPILLARY PRESSURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENETIC TRAIT; GENETIC VARIABILITY; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION RATE; HEALTH CARE ORGANIZATION; HOMOZYGOTE; HUMAN; HUMAN CELL; HYDROSTATIC PRESSURE; INFORMATION SCIENCE; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OPEN READING FRAME; PLEIOTROPY; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DENSITY;

EID: 70350664428     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.306     Document Type: Article

References (59)

1. Jose PA, Eisner GM, Felder RA. Renal dopamine receptors in health and hypertension. Pharmacol Ther 1998; 80: 149-182.
2. Zeng C, Armando I, Luo Y et al. Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice. Am J Physiol Heart Circ Physiol 2008; 294: H551-H569.
3. Albrecht FE, Drago J, Felder RA et al. Role of the D1A dopamine receptor in the pathogenesis of genetic hypertension. J Clin Invest 1996; 97: 2283-2288.
4. Jose PA, Eisner GM, Felder RA. Role of dopamine receptors in the kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens 2002; 11: 87-92.
5. O'Connell DP, Ragsdale NV, Boyd DG et al. Differential human renal tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status. Hypertension 1997; 29(1 Part 1): 115-122.
6. Sato M, Soma M, Nakayama T et al. Dopamine D1 receptor gene polymorphism is associated with essential hypertension. Hypertension 2000; 36: 183-186.
7. Staessen JA, Kuznetsova T, Zhang H et al. Blood pressure and renal sodium handling in relation to genetic variation in the DRD1 promoter and GRK4. Hypertension 2008; 51: 1643-1650.
8. Siragy HM, Felder RA, Howell NL et al. Evidence that intrarenal dopamine acts as a paracrine substance at the renal tubule. Am J Physiol 1989; 257(3 Part 2): F469-F477.
9. Rao F, Wessel J, Wen G et al. Renal albumin excretion: twin studies identify influences of heredity, environment, and adrenergic pathway polymorphism. Hypertension 2007; 49: 1015-1031.
10. Satoh N, Kikuchi K, Hasegawa T et al. The role of the renal dopaminergic and the prostaglandin systems in renal uric acid metabolism in patients with essential hypertension. Nippon Naibunpi Gakkai Zasshi 1991; 67: 1271-1281.
11. Ruilope LM, Robles RG, Miranda B et al. Renal effects of fenoldopam in refractory hypertension. J Hypertens 1988; 6: 665-669.
12. Luippold G, Osswald H, Muhlbauer B. Renal effects of exogenous dopamine: modulation by renal nerves and dopamine receptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 1998; 358: 445-451.
13. Edwards RM. Comparison of the effects of fenoldopam, SK & F R-87516 and dopamine on renal arterioles in vitro. Eur J Pharmacol 1986; 126: 167-170.
14. Takenaka T, Forster H, Epstein M. Characterization of the renal microvascular actions of a new dopaminergic (DA1) agonist, YM435. J Pharmacol Exp Ther 1993; 264: 1154-1159.
15. Pollock DM, Arendshorst WJ. Tubuloglomerular feedback and blood flow autoregulation during DA1-induced renal vasodilation. Am J Physiol 1990; 258(3 Part 2): F627-F635.
16. Loutzenhiser R, Griffin K, Williamson G et al. Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1153-R1167.
17. Haberle DA, Konigbauer B, Kawabata M et al. Renal blood flow control by tubuloglomerular feedback (TGF) in normal and spontaneously hypertensive rats-a role for dopamine and adenosine. Klin Wochenschr 1991; 69: 587-596.
18. Schnermann J, Todd KM, Briggs JP. Effect of dopamine on the tubuloglomerular feedback mechanism. Am J Physiol 1990; 258(4 Part 2): F790-F798.
19. Zeng C, Wang Z, Hopfer U et al. Rat strain effects of AT1 receptor activation on D1 dopamine receptors in immortalized renal proximal tubule cells. Hypertension 2005; 46: 799-805. (Pubitemid 43186755)
20. Salomone LJ, Howell NL, McGrath HE et al. Intrarenal dopamine D1-like receptor stimulation induces natriuresis via an angiotensin type-2 receptor mechanism. Hypertension 2007; 49: 155-161.
21. Yamaguchi I, Yao L, Sanada H et al. Dopamine D1A receptors and renin release in rat juxtaglomerular cells. Hypertension 1997; 29: 962-968. (Pubitemid 27152466)
22. Zhang MZ, Yao B, Fang X et al. Intrarenal dopaminergic system regulates renin expression. Hypertension 2009; 53: 564-570.
23. Harvey JN, Worth DP, Brown J et al. The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man. Br J Clin Pharmacol 1985; 19: 21-27.
24. Harvey JN, Worth DP, Brown J et al. Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension. Br J Clin Pharmacol 1986; 21: 53-61.
25. Dworkin LD, Ichikawa I, Brenner BM. Hormonal modulation of glomerular function. Am J Physiol 1983; 244: F95-F104.
26. Bek M, Fischer KG, Greiber S et al. Dopamine depolarizes podocytes via a D1-like receptor. Nephrol Dial Transplant 1999; 14: 581-587.
27. Shultz PJ, Sedor JR, Abboud HE. Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells. Am J Physiol 1987; 253(2 Part 2): H358-H364.
28. Arita DY, Di Marco GS, Schor N et al. Purification and characterization of the active form of tyrosine hydroxylase from mesangial cells in culture. J Cell Biochem 2002; 87: 58-64.
29. Di Marco GS, Naffah-Mazzacoratti G, Vio CP et al. Mesangial cells are able to produce catecholamines in vitro. J Cell Biochem 2003; 89: 144-151.
30. Felder RA, Seikaly MG, Cody P et al. Attenuated renal response to dopaminergic drugs in spontaneously hypertensive rats. Hypertension 1990; 15(6 Part 1): 560-569.
31. Wang YX, Gellai M, Brooks DP. Dopamine DA1 receptor agonist, fenoldopam, reverses glycine-induced hyperfiltration in rats. Am J Physiol 1992; 262(6 Part 2): F1055-F1060.
32. Barthelmebs M, Vailly B, Grima M et al. Effects of dopamine prodrugs and fenoldopam on glomerular hyperfiltration in streptozotocin-induced diabetes in rats. J Cardiovasc Pharmacol 1991; 18: 243-253.
33. Beige J, Bellmann A, Sharma AM et al. Ethnic origin determines the impact of genetic variants in dopamine receptor gene (DRD1) concerning essential hypertension. Am J Hypertens 2004; 17(12 Part 1): 1184-1187.
34. Lu Y, Zhu H, Wang X et al. Effects of dopamine receptor type 1 and Gs protein alpha subunit gene polymorphisms on blood pressure at rest and in response to stress. Am J Hypertens 2006; 19: 832-836.
35. Kahn AM. Indirect coupling between sodium and urate transport in the proximal tubule. Kidney Int 1989; 36: 378-384.
36. Quinones Galvan A, Natali A, Baldi S et al. Effect of insulin on uric acid excretion in humans. Am J Physiol 1995; 268(1 Part 1): E1-E5.
37. Johnson RJ, Kang DH, Feig D et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-1190.
38. Sulikowska B, Manitius J, Odrowaz-Sypniewska G et al. Uric acid excretion and dopamine-induced glomerular filtration response in patients with IgA glomerulonephritis. Am J Nephrol 2008; 28: 391-396.
39. Perlstein TS, Gumieniak O, Hopkins PN et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 2004; 66: 1465-1470.
40. Emmerson BT, Nagel SL, Duffy DL et al. Genetic control of the renal clearance of urate: a study of twins. Ann Rheum Dis 1992; 51: 375-377.
41. Galle J. Reduction of proteinuria with angiotensin receptor blockers. Nat Clin Pract Cardiovasc Med 2008; 5(Suppl 1): S36-S43.
42. Parola AL, Kobilka BK. The peptide product of a 50 leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis. J Biol Chem 1994; 269: 4497-4505.
43. Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci 2008; 65: 3168-3181.
44. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765-769.
45. Good PI. Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses. Springer-Verlag: New York, 1994.
46. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
47. Murthy K, Stevens LA, Stark PC et al. Variation in the serum creatinine assay calibration: a practical application to glomerular filtration rate estimation. Kidney Int 2005; 68: 1884-1887.
48. Peake M, Whiting M. Measurement of serum creatinine-current status and future goals. Clin Biochem Rev 2006; 27: 173-184.
49. Zhang L, Rao F, Wessel J et al. Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: prediction of catecholamines and response to stress in twins. Physiol Genomics 2004; 19: 277-291.
50. Brinton TJ, Kailasam MT, Wu RA et al. Arterial compliance by cuff sphygmomanometer. Application to hypertension and early changes in subjects at genetic risk. Hypertension 1996; 28: 599-603.
51. Rana BK, Insel PA, Payne SH et al. Population-based sample reveals gene-gender interactions in blood pressure in White Americans. Hypertension 2007; 49: 96-106.
52. Kupper N, Willemsen G, Riese H et al. Heritability of daytime ambulatory blood pressure in an extended twin design. Hypertension 2005; 45: 80-85.
53. Evans A, Van Baal GC, McCarron P et al. The genetics of coronary heart disease: the contribution of twin studies. Twin Res 2003; 6: 432-441.
54. Cullinan A, Cantor C. Sequenom, Inc. Pharmacogenomics 2008; 9: 1211-1215.
55. Do KA, Broom BM, Kuhnert P et al. Genetic analysis of the age at menopause by using estimating equations and Bayesian random effects models. Stat Med 2000; 19: 1217-1235.
56. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 1998; 62: 1198-1211.
57. Barrett JC, Fry B, Maller J et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
58. Faul F, Erdfelder E, Lang AG et al. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39: 175-191.
59. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.